title: CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis.
abstract: Myeloma tumor cells, both freshly excised and cultured, are extremely resistant to cell-mediated cytolysis. As evidence suggests that B-cell susceptibility to lysis is dependent upon its state of differentiation and activation, we tested the ability of a variety of B-cell proliferation and differentiation agents, including pokeweed mitogen (PWM), to enhance the sensitivity of myeloma cells to cell-mediated lysis. PWM was found to significantly enhance the susceptibility of myeloma cell lines and freshly isolated myeloma cells to interleukin-2 (IL-2)-activated cell-mediated cytolysis. This effect was seen with the use of both IL-2-stimulated natural killer (NK) cells and T cells as effectors. The enhanced sensitivity of myeloma cells to cytolysis correlated with an increase in their cell surface expression of CD9, a pre-B cell marker and member of the transmembrane 4 superfamily. Incubation of PWM-stimulated myeloma cells with either monoclonal antibodies or antisense oligonucleotides directed against CD9 abrogated the effect of PWM. In order to determine whether there was a direct relationship between the expression of CD9 and enhanced sensitivity to cytolysis, myeloma cell lines that lacked CD9 expression were transfected with the CD9 gene. The level of cell surface CD9 expression correlates with enhanced susceptibility to lysis. Therefore, CD9 appears to be an important component in enhancing the sensitivity of myeloma cells to lysis mediated by IL-2-activated T cells and NK cells.
authors.affiliation: Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
authors.forename: S
authors.initials: S
authors.lastname: Shallal
authors.forename: J
authors.initials: J
authors.lastname: Kornbluth
mesh_terms: D015703:Antigens, CD / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D001402:B-Lymphocytes / Q000276:immunology; D002118:Calcium / Q000378:metabolism; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins; D009101:Multiple Myeloma / Q000276:immunology*; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology*; D011043:Pokeweed Mitogens / Q000494:pharmacology; D011994:Recombinant Proteins / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology*; D060245:Tetraspanin 29; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; C554869:CD9 protein, human; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D020319:Oligodeoxyribonucleotides, Antisense; D011043:Pokeweed Mitogens; D011994:Recombinant Proteins; D060245:Tetraspanin 29; D002118:Calcium